11th congress of the french speaking society of transplantationKidney transplantation: ComplicationsSirolimus for the Treatment of Kaposi Sarcoma After Renal Transplantation: A Series of 10 Cases
Section snippets
Patients and Methods
We studied 307 kidney transplant recipients who underwent renal transplantations at our center between January 1994 and June 2010. All patients received induction treatment with polyclonal antibodies (antithymocyte globulins; ATG) and prednisolone (10 mg/kg/d). There were two distinct maintenance immunosuppressive regimens: from 1994 to 2003 we prescribed azathioprine (2 mg/kg/d), cyclosporine (5 mg/kg/d), and prednisone (10 mg/d), and from 2003 onwards, mycophenolate mofetil (MMF 2 g/d, then 1
Results
During the study period, 10 of 307 (3.25%) patients developed KS. The mean age of affected individuals at transplantation was 35.8 ± 8.7 years (range, 22 to 49 years). The 10 KS subjects included 7 males and 3 females. Their mean interval time between transplantation and KS occurrence was 24.7 ± 21.36 months (range, 6 to 64 months). The mean length of ATG treatment was 9.5 days (range, 6 to 13 days). Their mean duration of hemodialysis before transplantation was 41 ± 40.3 months (range, 1 to
Discussion
The incidence of KS among solid organ transplant recipients is 500 times that among the general population, suggesting a role for immunosupression in the development of the disease. HHV8 infection has been incriminated in the pathogenesis of KS lesions. In fact, the geographic distribution and detection of DNA fragments of HHV8 in KS skin lesions are suggestive of an infectious cause.1
The mean interval time between kidney transplantation and KS diagnosis is 29 to 31 months (range, 3 to 124
References (11)
- et al.
Kaposi sarcoma in transplantation
Transplant Rev (Orlando)
(2008) - et al.
Outcome of Kaposi's sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients
Transplant Proc
(2005) - et al.
Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma
Transplant Proc
(2005) - et al.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
Science
(1994) - et al.
Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression
Transpl Int
(2008)
Cited by (30)
Medical Treatment of Vascular Anomalies
2022, Dermatologic ClinicsCitation Excerpt :Although sirolimus is still currently only FDA approved as a transplant immunosuppressive, it has amassed many promising off-label uses including management of tuberous sclerosis (TS) renal angiomyolipomas,14 lymphangioleiomyomatosis,15,16 and TS subependymal giant cell astrocytomas.17,18 Sirolimus has shown utility in other cutaneous conditions as well, including Kaposi sarcoma,19,20 psoriasis,21 and lichen planus.22,23 Owing to the discovery of its antiproliferative and antitumor effects, sirolimus and its derivatives have played a significant role in cancer therapy and research.
Kaposi Sarcoma, De Novo, in a Kidney Transplant Surgical Scar
2021, Actas Dermo-SifiliograficasAdvances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
2015, Journal of the American Academy of DermatologyCitation Excerpt :The incidence of Kaposi sarcoma is increasing because of growing numbers of organ transplantation and immunosuppressed patients worldwide. Posttransplantation therapies that maintain immunosuppression to preserve graft function while blocking tumor formation are desired.47 Kaposi sarcomas are driven by vascular proliferation mutations in genes such as VEGF, some of which are inhibited by mTORIs (Fig 1), and 90% of these tumors are confined to the skin.47,48
Rapamycin promotes autophagy cell death of Kaposi’s sarcoma cells through P75NTR activation
2022, Experimental DermatologyMięsak kaposiego u biorcy przeszczepu nerki
2022, Przeglad Dermatologiczny